E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy

Antzeko izenburuak

• Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations
  nork: Claudiani, Simone, et al.
  Argitaratua: (2020)
• MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia
  nork: Claudiani, Simone, et al.
  Argitaratua: (2019)
• Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
  nork: Marin, David, et al.
  Argitaratua: (2012)
• Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors
  nork: Nteliopoulos, Georgios, et al.
  Argitaratua: (2019)
• The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib
  nork: Khorashad, Jamshid Sorouri, et al.
  Argitaratua: (2009)